Key Drivers
- High margins
- Strong FCF
- Limited liquidity
AIAI Summary
J&J has transitioned from a defensive cash-generator to a growth-at-scale company driven by late-stage biologics and MedTech commercialization—making the stock's upside now contingent on successful Phase‑3 readouts, strong launches, and a clean DePuy separation, while large litigation hits or trial failures would rapidly reverse the rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong FCF
- •Limited liquidity
J&J combines high margins and strong free cash flow supporting dividends with moderate leverage, weak short-term liquidity, and a heavy intangible asset base that warrant monitoring.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Tight support
- •Modest decline
Over the last month JNJ has softened into a near-term downtrend after peaking near $248.56 on 2026-03-02 and sliding toward $235.37 by 2026-03-20, with immediate support around $240–$242 and resistance near $248–$249 that will determine whether the pullback stabilizes or extends.
~5% drop from $248.56 (2026-03-02) to $235.37 (2026-03-20); last month change ~‑2.4%
Sentiment & News
Key News Insights:
- •Institutional buying
- •Oncology strength
- •Analyst optimism
J&J shares have rallied sharply (~70% peak) since early 2025 on improving technicals and fundamentals, analyst optimism and broad institutional accumulation led partly by oncology/Darzalex strength.
Sustained institutional inflows and positive clinical/sector catalysts should support further upside, though execution and pipeline results remain key risk drivers
Similar Companies in Healthcare
Other companies in the same sector with AI ratings